Clinical Trial Update: Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial of aflibercept in relapsed or refractory pediatric solid tumors completed; safety and pharmacokinetic data reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Unspecified Childhood Solid Tumor, Protocol Specific | Phase 1 | Status: COMPLETED